FDA approves Boehringer's once-a-day inhaler drug

(AP)—The Food and Drug Administration has approved a new long-acting inhaler drug from Boehringer Ingelheim to treat people with chronic lung disease.

The agency approved Striverdi Respimat for chronic , which causes bronchitis and emphysema and affects about 24 million people in the U.S. The disease, which is most often caused by smoking, is the third leading cause of death in the U.S., according to the National Institutes of Health.

The FDA approved the drug on Thursday based on a study in 3,104 patients which showed improvements in lung function versus placebo.

The drug will carry a bold warning that it is not approved to treat patients with asthma. Striverdi Respimate is part of a family of medications that have been linked to asthma-related deaths.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Tudorza pressair approved for COPD

Jul 24, 2012

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) ...

Anoro ellipta approved for COPD

Dec 18, 2013

(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.

Adempas approved to treat pulmonary hypertension

Oct 09, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

15 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.